You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

January 19, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

[BLOG]: A better IV compounding strategy: Leveraging in-house advantage

In the wake of ongoing fallout and a 2-year crackdown on compounding centers by FDA, many hospitals are analyzing their current strategy and rethinking the pros and cons of outsourced IV compounding. » Consider the advantages of in-house batch compounding as a viable option

FDA OKs carbidopa-levodopa enteral suspension for Parkinson's

FDA has approved carbidopa-levodopa (Duopa, AbbVie) enteral suspension for the treatment of patients with advanced Parkinson's disease. » Read more about Duopa

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA approves Gadavist for pediatric patients younger than 2

FDA has approved gadobutrol (Gadavist, Bayer HealthCare) injection for use with magnetic resonance imaging (MRI) in pediatric patients aged younger than 2 years to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. It is the first gadolinium-based contrast agent for patients aged younger than 2 years, including term neonates. » Details

 

RELATED ARTICLES

Compounded ingredient costs: PBMs take action

FDA approves Rytary for Parkinson's disease

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group